Company Description
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome.
It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Dec 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Dr. Omid C. Farokhzad M.D., Ph.D. |
Contact Details
Address: 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650-453-0000 |
| Website | seer.bio |
Stock Details
| Ticker Symbol | SEER |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001726445 |
| CUSIP Number | 81578P106 |
| ISIN Number | US81578P1066 |
| Employer ID | 82-1153150 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Chief Executive Officer, and Chair of the Board of Directors |
| David R. Horn | President,Treasurer and Chief Financial Officer |
| Elona Kogan Esq., J.D. | Chief Legal Officer,General Counsel and Secretary |
| Joe Laws | Chief Technology Officer and Co-Founder |
| Kenny Ross | Chief Operations and Product Officer |
| Marissa Dixon | Chief People Officer |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer |
| Martin Goldberg Ph.D. | Senior Vice President of Development |
| Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research and Tech Development |
| Dr. Christopher E. Mason Ph.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |